• Merck, a leading science and technology company, today announced the presentation of new analyses from the MAVENCLAD ® (cladribine tablets) MAGNIFY-MS study, which demonstrated that patients with relapsing multiple sclerosis (RMS) experienced sustained reduction in serum neurofilament light chain (NfL), indicating that MAVENCLAD reduced neuronal injury over two years. (businesswire.com)
  • Because of its safety profile, use of MAVENCLAD is generally recommended for patients who have had an inadequate response to, or are unable to tolerate, an alternate drug indicated for the treatment of multiple sclerosis (MS), and MAVENCLAD is not recommended for use in patients with clinically isolated syndrome (CIS). (businesswire.com)
  • Cladribine, sold under the brand name Mavenclad, is used for the treatment of adults with highly active forms of relapsing-remitting multiple sclerosis. (wikipedia.org)
  • one newer medication, cladribine (brand name Mavenclad), is taken in two treatment courses, once a year for two years. (rush.edu)
  • Additionally, at ACTRIMS, data will be presented that includes analyses of the CLARIFY-MS study, showing the potential of MAVENCLAD® (cladribine tablets) to improve outcomes in an impactful way for people living with RMS. (koreanewswire.co.kr)
  • If you have a certain kind of multiple sclerosis (MS) , your doctor may recommend treatment with Mavenclad. (healthline.com)
  • Mavenclad is a prescription drug used to treat relapsing types of multiple sclerosis (MS) in adults. (healthline.com)
  • The mean percentage brain volume loss per year was significantly reduced in patients treated with Cladribine Tablets 3.5 mg/kg (--0.56%±0.68, p=0.010, n=336) and 5.25 mg/kg (--0.57%±0.72, p=0.019, n=351) compared with patients treated with placebo (--0.70%±0.79, n=338). (disabled-world.com)
  • Objectives: Use real-world data to compare treatment patterns and clinical outcomes in people with MS (pwMS) treated with cladribine tablets versus other oral DMTs. (monash.edu)
  • We herein provide a comprehensive assessment of magnetic resonance imaging (MRI) outcomes from CLARITY, a 96-week, double-blind study demonstrating significant clinical and MRI improvements in patients with relapsing-remitting multiple sclerosis (RRMS) treated with cladribine tablets. (regionh.dk)
  • The post hoc analysis showed that Cladribine Tablets reduced the annualised rate of brain volume loss - also known as brain atrophy - compared with placebo in patients with relapsing remitting multiple sclerosis (RRMS). (disabled-world.com)
  • Following EMA approval of cladribine tablets for the treatment of adult patients with highly active relapsing-remitting multiple sclerosis in 2017, as of July 2020, cladribine tablets have gained marketing authorisation in over 75 countries. (wikipedia.org)
  • Use of cladribine tablets is recommended only if a person has rapidly evolving severe relapsing-remitting multiple sclerosis, that is, at least two relapses in the previous year and at least one T1 gadolinium-enhancing lesion at baseline MRI or relapsing-remitting multiple sclerosis that has responded inadequately to treatment with disease-modifying therapy, defined as one relapse in the previous year and MRI evidence of disease activity. (acnr.co.uk)
  • Conclusion: Additional patient-years of observation do not significantly alter the conclusions of earlier interim analyses, and no new major safety findings were identified in this consolidated analysis of safety data of cladribine tablets 3.5 mg/kg monotherapy in patients with relapsing-remitting multiple sclerosis. (uab.cat)
  • Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study. (qxmd.com)
  • In the 2-year CLARITY study, cladribine tablets significantly improved clinical and magnetic resonance imaging (MRI) outcomes (vs placebo) in patients with relapsing-remitting multiple sclerosis (MS). (qxmd.com)
  • Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis. (nih.gov)
  • A Phase IIIb, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group, Extension Trial to Evaluate the Safety and Tolerability of Oral Cladribine in Subjects with Relapsing-Remitting Multiple Sclerosis Who Have Completed Trial 25643 (CLARITY). (clinicaltrialsregister.eu)
  • Results: Cohorts included 633 pwMS receiving cladribine tablets, 1195 receiving fingolimod, 912 receiving dimethyl fumarate, and 735 receiving teriflunomide. (monash.edu)
  • As well in both studies, very few patients receiving cladribine tablets switched to other therapies. (businesswire.com)
  • 18 weeks) in patients starting alemtuzumab, rituximab, ocrelizumab or cladribine following FTY discontinuation. (mssm.edu)
  • By July'19 Ocrelizumab, Alemtuzumab and Cladribine were included. (medworm.com)
  • It will be the first to compare how effectively autologous hematopoietic stem cell transplantation (AHSCT) is when compared with four other highly effective drug treatments which have shown great promise in clinical trials (alemtuzumab, ocrelizumab, ofatumumab and cladribine). (sheffield.ac.uk)
  • Additional data include two real-world evidence (RWE) studies, which indicated an increase in the use of cladribine tablets in treatment-naïve patients and demonstrated low levels of switching to other disease-modifying therapies (DMTs) up to four years. (businesswire.com)
  • Children and teens with multiple sclerosis are treated with the same therapies as adults, but they are considered "off label" for treating children, (not an FDA approved the use of the drug, but it is/may be effective for some people with the condition). (medicinenet.com)
  • 4 Monitoring is limited to the first two years only, meaning that cladribine tablets have the lowest administration and monitoring burden of all available high efficacy disease modifying therapies. (acnr.co.uk)
  • Maintaining an active, healthy life is possible with the latest treatments for MS. The RUSH Multiple Sclerosis Center at RUSH University Medical Center in Chicago offers about 20 different therapies, from pills to injections to infusions. (rush.edu)
  • As many as 80 percent of people with multiple sclerosis (MS) choose to incorporate non-traditional therapies into their treatment plan. (mymsteam.com)
  • Treatment of multiple sclerosis (MS) has 2 aspects: immunomodulatory therapy (IMT) for the underlying immune disorder and therapies to relieve or modify symptoms. (medscape.com)
  • Cladribine, sold under the brand name Leustatin, among others, is a medication used to treat hairy cell leukemia (leukemic reticuloendotheliosis) and B-cell chronic lymphocytic leukemia. (wikipedia.org)
  • LEUSTATIN (cladribine) Injection should be administered under the supervision of a qualified physician experienced in the use of antineoplastic therapy. (nih.gov)
  • LEUSTATIN (cladribine) Injection (also commonly known as 2-chloro-2΄-deoxy- β -D-adenosine) is a synthetic antineoplastic agent for continuous intravenous infusion. (nih.gov)
  • LEUSTATIN Injection is available in single-use vials containing 10 mg (1 mg/mL) of cladribine, a chlorinated purine nucleoside analog. (nih.gov)
  • In addition, the analysis found that patients with lower rates of brain atrophy showed the highest probability of remaining free from disability progression at two years.1 This supports existing findings that increased brain volume loss over time is associated with worse clinical outcomes such as increased disability progression and cognitive changes, in patients with multiple sclerosis. (disabled-world.com)
  • The mechanism by which cladribine exerts its therapeutic effects in patients with multiple sclerosis has not been fully elucidated but is thought to involve cytotoxic effects on B and T lymphocytes through impairment of DNA synthesis, resulting in depletion of lymphocytes. (businesswire.com)
  • Phase III CLARITY study data revealed significant reduction in brain atrophy in patients on short course of investigational Cladribine Tablets over two years. (disabled-world.com)
  • Post hoc analysis of Phase III CLARITY study data recently published in Multiple Sclerosis Journal showed statistically significant reduction in brain atrophy in patients on a short course of investigational Cladribine Tablets over two years compared with patients receiving placebo. (disabled-world.com)
  • Merck KGaA, Darmstadt, Germany, a leading science and technology company, operating as EMD Serono in Canada, today announced the publication of the results of a post hoc analysis of the Phase III CLARITY study in Multiple Sclerosis Journal . (disabled-world.com)
  • The CLARITY study was a two-year (96-week), randomised, double-blind, placebo-controlled Phase III study of Cladribine Tablets in 1,326 people with RRMS. (disabled-world.com)
  • The brain atrophy analysis evaluated the effect of Cladribine tablets on brain volume loss (BVL) over 2 years in RMS and the association of BVL with confirmed disability progression in 1,025 (77.3%) of the patients in CLARITY. (disabled-world.com)
  • in patients treated with cladribine 3.5 mg/kg in CLARITY, approximately 75% remained relapse-free when given placebo during the Extension. (qxmd.com)
  • Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study. (msdiscovery.org)
  • Cladribine tablets received marketing authorisation from the European Commission in August 2017 based on an extensive 12-year clinical trial programme. (acnr.co.uk)
  • Eligible pwMS started treatment with cladribine, fingolimod, dimethyl fumarate, or teriflunomide tablets from 2018 to mid-2021 and were censored at treatment discontinuation/switch, death, loss to follow-up, pregnancy, or study period end. (monash.edu)
  • Individuals treated with fingolimod, dimethyl fumarate, or teriflunomide switched treatment significantly more quickly than matched cladribine tablet cohorts (adjusted hazard ratio (95% confidence interval): 4.00 (2.54-6.32), 7.04 (4.16-11.93), and 6.52 (3.79-11.22), respectively). (monash.edu)
  • Cladribine is given as an intravenous (into the vein) injection. (rxhealthmed.ca)
  • The EvolutionRMS study looked at a medication called evobrutinib for people with relapsing multiple sclerosis (RMS) with relapses. (massgeneral.org)
  • These data also continue to demonstrate its treatment benefit in reducing annualized relapse rates (ARR) over four years in people with relapsing multiple sclerosis (RMS). (koreanewswire.co.kr)
  • Evobrutinib is an oral, CNS-penetrating, highly selective inhibitor of Bruton's tyrosine kinase (BTK) in clinical development as a potential treatment for relapsing multiple sclerosis (RMS). (koreanewswire.co.kr)
  • Alert MS Drug Ocrelizumab (Ocrevus) Approved in Europe The European Commission clears the anti-CD20 monoclonal antibody for adults with relapsing multiple sclerosis and early primary progressive multiple sclerosis. (medscape.com)
  • Once inside a cell, cladribine undergoes phosphorylation by the enzyme deoxycytidine kinase (DCK) to produce mononucleotide 2-chlorodeoxyadenosine 5'monophosphate (2-CdAMP), which is subsequently phosphorylated to the triphosphorylated active compound 2-chlorodeoxyadenosine 5'triphosphate (2-CdATP). (wikipedia.org)
  • These findings reinforce and expand on the consistent and positive effect of Cladribine Tablets in improving clinically relevant outcomes, such as reducing relapse rate and disability, and further our resolve to make this investigational therapy available for patients living with RRMS," said Steven Hildemann, MD, PhD, Global Chief Medical Officer and Head of Global Medical Affairs and Safety, Merck KGaA, Darmstadt, Germany. (disabled-world.com)
  • Patients with RRMS were randomized 1:1:1 to annual short-course therapy with cladribine tablets cumulative dose 3.5 or 5.25 mg/kg or placebo. (regionh.dk)
  • These findings reinforce and expand on the consistent and positive effect of Cladribine Tablets in improving clinically relevant outcomes, such as reducing relapse rate and disability. (disabled-world.com)
  • Conclusion: Cladribine tablets were associated with a significantly greater real-world treatment persistence and more favorable relapse outcomes than all oral DMT comparators. (monash.edu)
  • The MASTER-2 trial is an observational study to evaluate the effectiveness and patient-reported outcomes in people with relapsing forms of multiple sclerosis who are transitioning from ocrelizumab to cladribine. (massgeneral.org)
  • Aubagio is a prescription medication approved by the Food and Drug Administration (FDA) for treating adults with relapsing forms of multiple sclerosis (MS). It is also known by its drug name, Teriflunomide. (mymsteam.com)
  • Cladribine is used as a first- and second-line treatment for symptomatic hairy cell leukemia and for B-cell chronic lymphocytic leukaemia, and is administered by intravenous or subcutaneous infusion. (wikipedia.org)
  • Approved by the FDA in 1993, the drug cladribine offered hope for the then-fatal blood cancer called hairy cell leukemia, or HCL, and was soon expanded as a therapy for multiple sclerosis. (nfcr.org)
  • MRI-measured disease activity was significantly reduced in both cladribine tablets groups versus placebo. (regionh.dk)
  • Standardized incidence ratios for malignancies were calculated in relation to a matched GLOBOCAN reference population, and risk differences (cladribine tablets versus placebo) were estimated. (uab.cat)
  • Results: The Monotherapy Oral cohort comprised 923 patients who received cladribine tablets 3.5 mg/kg and 641 patients who received placebo. (uab.cat)
  • Overall, the reported number of SAEs was higher in the cladribine tablets 3.5 mg/kg group (133/923 [14.4%] patients with at least 1 SAE), versus the placebo group (68/641 [10.6%] patients with at least 1 SAE). (uab.cat)
  • There was no difference between the cladribine tablets 3.5 mg/kg group and placebo in the overall incidence of infections. (uab.cat)
  • cladribine recipients were re-randomized 2:1 to cladribine 3.5 mg/kg or placebo, with blind maintained. (qxmd.com)
  • Adverse event rates were generally similar between groups, but lymphopenia Grade ⩾ 3 rates were higher with cladribine than placebo (Grade 4 lymphopenia occurred infrequently). (qxmd.com)
  • 90% of those treated with cladribine 3.5 mg/kg and all treated with placebo in the Extension, recovered to Grade 0-1 by study end. (qxmd.com)
  • Cladribine tablets treatment for 2 years followed by 2 years' placebo treatment produced durable clinical benefits similar to 4 years of cladribine treatment with a low risk of severe lymphopenia or clinical worsening. (qxmd.com)
  • To evaluate the efficacy and safety of oral masitinib versus placebo in the treatment of patients with primary progressive or secondary progressive multiple sclerosis without relapse. (ichgcp.net)
  • Masitinib is a selective tyrosine kinase inhibitor, targeting innate immune cells (mast cells and microglia) that are involved in the pathophysiology of progressive multiple sclerosis (MS). This is a multicenter, double-blind, randomized, placebo-controlled, comparative study of oral masitinib in the treatment of patients with progressive MS who were progressing but not clinically active. (ichgcp.net)
  • Objective: To report on safety and effectiveness of subcutaneous cladribine (Litak ® ) in multiple sclerosis (MS) patients. (lu.se)
  • Effectiveness in relapsing MS appeared similar to cladribine tablets and was encouraging in progressive MS. Our data suggest cladribine may be safe and effective in MS-patients irrespective of their disease stage. (lu.se)
  • Background: Effectiveness of cladribine tablets, an oral disease-modifying treatment (DMT) for multiple sclerosis (MS), was established in clinical trials and confirmed with real-world experience. (monash.edu)
  • Accelerated development of a proprietary Cladribine ODF formulation for the treatment of MS has become a top priority for BioNxt," said Hugh Rogers, CEO & Director of BioNxt. (khon2.com)
  • Cladribine tablet cohorts had significantly longer time-to-treatment discontinuation, time to first relapse, and lower ARR, compared with other oral DMT cohorts. (monash.edu)
  • Two real-world studies also presented at ECTRIMS-ACTRIMS reinforce the potential benefits of initiating treatment with cladribine tablets in the earlier stages of the disease. (businesswire.com)
  • Over time, an increasing trend in treatment initiation among treatment-naïve patients was observed, suggesting an advantage of early utilization of cladribine treatment. (businesswire.com)
  • In 2019, cladribine tablets were approved by the FDA for the treatment of relapsing forms of multiple sclerosis, to include relapsing-remitting disease and active secondary progressive disease, in adult patients who have had an inadequate response to, or are unable to tolerate, an alternate drug indicated for the treatment of multiple sclerosis. (wikipedia.org)
  • Cladribine tablets are taken for a maximum of 10 days in the first year and a maximum of 10 days in the second year, with no additional treatment needed in years three and four. (acnr.co.uk)
  • Patients can take cladribine tablets at home from the first dose as treatment does not require hospital administration. (acnr.co.uk)
  • however, severe neurological toxicity has been reported rarely following treatment with standard cladribine dosing regimens. (nih.gov)
  • To assess the safety and efficacy of cladribine treatment in a 2-year Extension study. (qxmd.com)
  • No clinical improvement in efficacy was apparent following further treatment with cladribine tablets after the initial 2-year treatment period in this trial setting. (qxmd.com)
  • Rituximab for the treatment of multiple sclerosis: a review. (nih.gov)
  • Data will be presented at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2023, taking place February 23-25. (koreanewswire.co.kr)
  • A team from Sheffield Teaching Hospitals NHS Foundation Trust led by two University of Sheffield Honorary Professors, are pioneering a breakthrough treatment in the UK for multiple sclerosis (MS). (sheffield.ac.uk)
  • A world-first trial is investigating if stem cell transplantation could be used in patients with aggressive multiple sclerosis (MS) as a first-line treatment. (sheffield.ac.uk)
  • It has been demonstrated that early treatment with interferon-beta can reduce the risk of developing multiple sclerosis. (salesandmarketingnetwork.com)
  • Cladribine is taken up by specific nucleoside transporter proteins. (wikipedia.org)
  • VANCOUVER, BC / ACCESSWIRE / November 20, 2023 / BioNxt Solutions Inc. (" BioNxt " or the " Company ") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to provide further details on its clinical and commercialization strategy for its recently announced 100% Cladribine IP acquisition and related clinical programs. (khon2.com)
  • In just a few years the Cladribine tablet market has reached greater than $1 billion dollars in annual sales and we see several potential advantages for an ODF product versus tablets. (khon2.com)
  • Cladribine plasma concentration after intravenous administration declines multi-exponentially with an average half-life of 6.7 +/- 2.5 hours. (nih.gov)
  • Multiple sclerosis (MS) is a chronic, inflammatory condition of the central nervous system and is the most common, non-traumatic, disabling neurological disease in young adults. (disabled-world.com)
  • 3 Last week, NICE issued a Final Appraisal Determination (FAD) that recommends cladribine tablets as an option for treating highly active MS in adults. (acnr.co.uk)
  • Multiple Sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system affecting young adults. (pairscongress.com)
  • Multiple sclerosis (MS) is the most common disabling neurological disease of young adults with symptom onset generally occurring between the ages of 20 to 40 years. (nih.gov)
  • We have conducted focus groups and mixed methods studies in New England, Puerto Rico, and Mississippi in English and Spanish with people with the diagnosis of multiple sclerosis to discuss and report their lived experiences with the CDC- defined social determinants of health as they apply to multiple sclerosis. (massgeneral.org)
  • This medication may be available under multiple brand names and/or in several different forms. (rxhealthmed.ca)
  • Do not use cladribine if you are allergic to cladribine or any ingredients of the medication. (rxhealthmed.ca)
  • Gilenya is a medication used to treat symptoms of multiple sclerosis (MS) . MS is a chronic disease where the immune system attacks the nervous system cells, slowing down the signals sent between cells. (canadadrugsdirect.com)
  • Multiple sclerosis (MS) is a chronic condition where the immune system attacks the protective myelin layer that covers your nerves. (healthline.com)
  • A forum to discuss Chronic Cerebrospinal Venous Insufficiency and its relationship to Multiple Sclerosis. (thisisms.com)
  • Multiple sclerosis (MS) is a chronic immune mediated neurodegenerative disease of the central nervous system with US prevalence of ∼900,000 and high economic burden. (medworm.com)
  • As well as interfering with the genetic material DNA of cancer cells, cladribine can interfere with some of your normal cells. (rxhealthmed.ca)
  • Evidence shows that brain atrophy in general accumulates throughout the course of multiple sclerosis and is associated with disability progression. (disabled-world.com)
  • However herpetic infection AEs occurred more frequently in the cladribine tablets 3.5 mg/kg group (driven primarily by herpes zoster, followed by oral herpes and herpes simplex). (uab.cat)
  • LCH can also involve multiple organs and systems, with clinically significant symptoms and consequences. (medscape.com)
  • Cladribine (2-chloro-2'-deoxyadenosine [2-CdA]) is a purine analogue that selectively targets and suppresses lymphocytes implicated in the underlying pathogenesis of multiple sclerosis and B-cell leukaemia. (wikipedia.org)
  • As a purine analogue, cladribine (2-chloro-2'-deoxyadenosine [2-CdA]) is taken up into rapidly proliferating cells, including B and T lymphocytes, to be incorporated into DNA synthesis. (wikipedia.org)
  • [ 1 , 2 ] Approximately 15% of patients with MS experience a primary progressive course from onset, either without preceding relapses (known as primary progressive multiple sclerosis [PPMS]) or with superimposed neurologic events, known as progressive relapsing MS. (medscape.com)
  • Rebif (interferon beta-1a) is a disease-modifying drug used to treat relapsing forms of multiple sclerosis (MS) and is similar to the interferon beta protein produced by the human body. (salesandmarketingnetwork.com)
  • 3.5 mg/kg cumulative dose over 2 years, referred to as cladribine tablets 3.5 mg/kg), which is approved in Europe and the USA. (uab.cat)
  • We searched PubMed and Medline for studies published during the last 10 years with the general term "optic neuritis" and specific terms like "typical optic neuritis," "atypical optic neuritis," "multiple sclerosis," "neuromyelitis optic neuritis," and "myelin oligodendrocyte glycoprotein antibody. (lww.com)
  • Most commonly, multiple sclerosis begins between the ages of 20 and 40, but it can begin anytime between ages 15 and 60 years. (msdmanuals.com)
  • Where people spend the first 15 years of life affects their chance of developing multiple sclerosis. (msdmanuals.com)
  • In the FAD, NICE concluded that cladribine tablets are less costly than other treatments and require less frequent dosing and monitoring requirements. (acnr.co.uk)
  • [ 12 ] In contrast, multiple bone lesions, alone or in association with a nonrisk site, may, although nonfatal, require 1 year of therapy with combination treatments such as prednisone plus vincristine. (medscape.com)
  • GENEVA, Switzerland, December 12 (HSMN NewsFeed) -- Serono (virt-x: SEO and NYSE: SRA) announced today the initiation of a Phase III clinical trial to evaluate the effect of two dosage regimens of the new formulation of Rebif (interferon beta-1a 44 mcg, three times a week or once a week) on the time to conversion to multiple sclerosis (MS) in people with first clinical symptoms suggestive of the disease. (salesandmarketingnetwork.com)
  • In a separate study out of Latin America, data was analyzed from 1,421 patients who received at least one course of cladribine tablets. (businesswire.com)
  • The £2.3m StarMS study , which has already opened its doors to patients in Sheffield, is now being launched in multiple sites across the UK. (sheffield.ac.uk)
  • The REFLEX study will determine the respective therapeutic benefit of two different dosage regimens of the new formulation of Rebif for people at risk of developing multiple sclerosis. (salesandmarketingnetwork.com)
  • While it's possible for some DMTs to be infused at home, most people choose to come to the RUSH Multiple Sclerosis Center. (rush.edu)
  • Here we provide the final report on the integrated analysis of the safety profile of cladribine tablets 3.5 mg/kg from the clinical development program, including final data from the PREMIERE registry. (uab.cat)
  • MS represents the largest market segment for the sale of Cladribine with approximately 2.3 million people living with MS worldwide, with the highest prevalence in North America and Europe. (khon2.com)
  • Cladribine tablets should not be taken by certain people, including immunocompromised patients and pregnant women. (acnr.co.uk)
  • It doesn't appear as if people with multiple sclerosis (MS) have an increased risk of contracting COVID-19 . (healthline.com)
  • Multiple sclerosis (MS) is a disease that looks different in everyone who has it - and you may know more people who have it than you think. (rush.edu)
  • Like everyone else, people with multiple sclerosis (MS) feel their best when they consistently eat a healthy, balanced diet. (mymsteam.com)
  • In most people with multiple sclerosis, periods of relatively good health alternate with episodes of worsening symptoms, but over time, multiple sclerosis gradually worsens. (msdmanuals.com)
  • World wide, about 2.8 million people have multiple sclerosis, and about 107,000 people are diagnosed with multiple sclerosis each year. (msdmanuals.com)
  • Most people with multiple sclerosis have periods of relatively good health (remissions) alternating with periods of worsening symptoms (flare-ups or relapses). (msdmanuals.com)
  • Also, multiple sclerosis is more likely to develop in people with certain genetic markers on the surface of their cells. (msdmanuals.com)
  • Cladribine belongs to the group of cancer-fighting medications known as antineoplastics , and specifically to the group of antineoplastics known as antimetabolites . (rxhealthmed.ca)
  • Cladribine fights cancer by preventing the growth of cancer cells, which eventually results in their destruction. (rxhealthmed.ca)
  • 5 drug groups), cancer (14 drugs) and multiple sclerosis (2 drugs). (who.int)
  • In general, the apparent volume of distribution of cladribine is approximately 9 L/kg, indicating an extensive distribution in body tissues. (nih.gov)
  • Usually, doctors diagnose multiple sclerosis based on symptoms and results of a physical examination and magnetic resonance imaging. (msdmanuals.com)
  • The Company has filed Cladribine ODF-related preliminary patent applications with three to four patent applications expected to be on file in major international jurisdictions by late 2024 to early 2025 with potential patent protection extending to 2044. (khon2.com)
  • Multiple sclerosis is a disease that involves an immune-mediated process that results in an abnormal response in the body's immune system that damages central nervous system (CNS) tissues in which the immune system attacks myelin, the substance that surrounds and insulates nerve fibers causing demyelination that leads to nerve damage. (medicinenet.com)